4:58 PM
 | 
Aug 30, 2013
 |  BC Extra  |  Clinical News

Teva drops Nuvigil for depression

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said it will not proceed with regulatory applications for Nuvigil armodafinil to treat adults with major depression associated with bipolar I disorder. The news came after data from the Phase III...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >